Beta Bionics (NASDAQ:BBNX) Shares Down 8% – What’s Next?

Beta Bionics, Inc. (NASDAQ:BBNX) was down 8% during trading on Friday . The stock traded as low as $13.16 and last traded at $13.1330. Approximately 334,288 shares were traded during mid-day trading, a decline of 70% from the average daily volume of 1,129,826 shares. The stock had previously closed at $14.27.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Stifel Nicolaus dropped their price objective on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Truist Financial lifted their target price on Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Bank of America lowered their target price on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a report on Monday, May 18th. The Goldman Sachs Group increased their price target on Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Beta Bionics in a report on Friday, July 17th. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $20.10.

Beta Bionics Stock Performance

The stock’s fifty day moving average is $14.99 and its two-hundred day moving average is $13.21. The firm has a market cap of $577.22 million, a price-to-earnings ratio of -7.78 and a beta of 3.04.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The firm had revenue of $32.01 million for the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. Sell-side analysts predict that Beta Bionics, Inc. will post -2.14 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Steven Jon Russell sold 4,222 shares of Beta Bionics stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total transaction of $53,239.42. Following the sale, the insider owned 173,849 shares of the company’s stock, valued at approximately $2,192,235.89. The trade was a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mike Mensinger sold 4,378 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total value of $55,206.58. Following the completion of the transaction, the insider directly owned 184,415 shares of the company’s stock, valued at $2,325,473.15. This trade represents a 2.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 40,351 shares of company stock valued at $553,961 in the last ninety days. Insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Evanson Financial LLC acquired a new position in shares of Beta Bionics during the second quarter valued at $490,000. Perceptive Advisors LLC lifted its holdings in Beta Bionics by 39.8% in the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after purchasing an additional 240,000 shares during the period. Eversept Partners LP lifted its holdings in Beta Bionics by 108.6% in the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock worth $14,177,000 after purchasing an additional 736,576 shares during the period. Quantinno Capital Management LP grew its position in Beta Bionics by 112.9% in the 1st quarter. Quantinno Capital Management LP now owns 67,879 shares of the company’s stock valued at $680,000 after buying an additional 35,996 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new position in Beta Bionics in the 1st quarter valued at about $720,000.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.